Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
| Treament |
Trials |
|
|
| clinical deterioration | clinical improvement | deaths | viral clearance |
| IFN alpha | 2 | 0.52 [0.02; 15.78], 1 RCT, I2=0%
inconclusive result | 1.28 [0.53; 3.09], 2 RCTs, I2=54% demonstrated
inconclusive result | 1.93 [0.24; 15.47], 3 RCTs, I2=0%
inconclusive result | 2.90 [1.64; 5.14], 3 RCTs, I2=0%
moderate degree of certainty | |
| SNG001 inhaled interferon beta | 2 | 0.65 [0.42; 1.00], 2 RCTs, I2=0%
inconclusive result | 2.32 [1.07; 5.04], 1 RCT, I2=0%
unassessable degree of certainty | 0.72 [0.35; 1.48], 2 RCTs, I2=0%
inconclusive result | - | |
| recombinant super-compound interferon rSIFN-co | 1 | 0.52 [0.02; 15.78], 1 RCT, I2=0%
inconclusive result | 1.76 [1.10; 2.81], 1 RCT, I2=0% demonstrated
unassessable degree of certainty | 1.04 [0.02; 53.73], 1 RCT, I2=0%
inconclusive result | 7.68 [0.91; 65.15], 1 RCT, I2=0%
inconclusive result | |
